Trial Profile
Phase II/III study of the tolerance and efficacy of combined use of didanosine (2',3'-dideoxyinosine; ddI) and lentinan in HIV-positive patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Didanosine (Primary) ; Lentinan (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 11 Oct 2005 New trial record.